COMPANY

Acurx Pharmaceuticals

HQ: Staten Island, NY source · acurxpharma.com ↗ · Mid-Atlantic

Acurx Pharmaceuticals is a publicly held, clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration. From company website Source · Oct 12, 2026

Keywords: Clostridium Difficile Infection Recurrence Clostridium Difficile Infection Ibezapolstat

Location: Staten Island, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

$1.1MRaised (2 yrs)2Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Form D reports $4.59M in warrant exercise value (filed Apr 29, 2026). SEC Form D 0001736243-26-000001 (Apr 29, 2026)
Evidence (1 event)
- Apr 29, 2026 · SEC Form D 0001736243-26-000001
  Name of Issuer: Acurx Pharmaceuticals, Inc.; CIK: 1736243; Address: Staten Island, NY; Submission type: D; Filing date: 2026-04-29; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-15; Types of Securities Offered: Security to be acquired; Business combination transaction: false; Total Offering Amount: 4587473; Total Amount Sold: 4587473; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Aug 6, 2026 Trial start Phase 2: ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection source ↗
Mar 7, 2025 Raise Follow-on offering — Registered direct: $1.1M (total, as published), announced Mar 7, 2025. Source: SEC filing. source ↗
Mar 6, 2020 Trial start Phase 2: ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection source ↗

Upcoming milestones

Sep 29, 2027 (ESTIMATED) · Phase 2 · ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection · NCT07513285

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $1.1M. Last 2 years.

Mar 7, 2025 Follow-on offering — Registered direct: $1.1M (total, as published), announced Mar 7, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07513285	ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection	Phase 2	Recruiting	Aug 6, 2026	Sep 29, 2027 (estimated)
NCT04247542	ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection	Phase 2	Completed	Mar 6, 2020	Oct 3, 2023 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-04-29 Raise Private raise (SEC Form D): $4.6M sold; issuer “Acurx Pharmaceuticals, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-06-27 Raise Private raise (SEC Form D): $4.0M sold; issuer “Acurx Pharmaceuticals, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-05-20 Raise Private raise (SEC Form D): amount sold not stated; issuer “Acurx Pharmaceuticals, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-03-21 Raise Private raise (SEC Form D): $3.4M sold; issuer “Acurx Pharmaceuticals, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-01-17 Raise Private raise (SEC Form D): $2.4M sold; issuer “Acurx Pharmaceuticals, Inc.”. Verified from the SEC filing. SEC filing ↗